Stefan Schmiedel

TL;DR: In this paper, the causes of COVID-19-related deaths were investigated in a single academic medical center in the German federal state of Hamburg for patients dying with a polymerase chain reaction-confirmed diagnosis of CoV-19 patients.

TL;DR: RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.

TL;DR: Among the patients with EVD who were cared for in the United States or Europe, close monitoring and aggressive supportive care that included intravenous fluid hydration, correction of electrolyte abnormalities, nutritional support, and critical care management for respiratory and renal failure were needed; 81.5% of these patients who received this care survived.

TL;DR: Intensive supportive treatment consisting of high-volume fluid resuscitation, broad-spectrum antibiotic therapy, and ventilatory support resulted in full recovery without the use of experimental therapies, suggesting that even severe EVD can be treated effectively with routine intensive care.

TL;DR: It is demonstrated that sustained sub-clinical cognitive impairments might be a common complication after recovery from COVID-19 in young adults, regardless of clinical course that were unmasked by the diagnostic approach.